SCHEMBL22084667

SCHEMBL22084667

Cc1ccc(S(=O)(=O)OCCCCCc2ccc(C(=O)OC(C)(C)C)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PSMD10 O75832 1/20 0.47
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
ENPP1 P22413 1/20 0.40
STAT3 P40763 1/20 0.40
KMT2A Q03164 4/20 0.39
CYP4A11 Q02928 2/20 0.39
CYP4F2 P78329 1/20 0.39
MAPT P10636 1/20 0.38
FKBP1A P62942 1/20 0.38
GAA P10253 1/20 0.38
MEN1 O00255 2/20 0.37
POLB P06746 1/20 0.37
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22032136 0.86 CA12 (0.44) PSMD10CA12CA1CA2CA9
SCHEMBL22032152 0.84 STAT3 (0.55) PSMD10ENPP1STAT3KMT2AMAPT
SCHEMBL9253387 0.83 PSMD10 (0.47) PSMD10ENPP1STAT3KMT2AMAPT
SCHEMBL5068482 0.82 PSMD10 (0.65) PSMD10CA12CA1CA2CA9
SCHEMBL9720181 0.82 CA12 (0.45) CA12CA1CA2CA9CA14
SCHEMBL14339870 0.80 CA2 (0.43) PSMD10CA12CA1CA2CA9
SCHEMBL28950664 0.80 SLC16A3 (0.41) PSMD10CA12CA1CA2CA9
SCHEMBL28950648 0.80 SLC16A3 (0.41) PSMD10CA12CA1CA2CA9
SCHEMBL9252362 0.79 PSMD10 (0.50) PSMD10ENPP1STAT3KMT2AMAPT
SCHEMBL8499603 0.79 CA2 (0.53) CA12CA1CA2CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11518763-B2 Macrocyclic compound and use thereof SCOHIA PHARMA, INC. (JP) 2022-12-06 US disclosed
US-11518763-B2 Macrocyclic compound and use thereof SCOHIA PHARMA, INC. (JP) 2022-12-06 US disclosed
US-20220119391-A1 MACROCYCLIC COMPOUND AND USE THEREOF SCOHIA PHARMA, INC. (JP) 2022-04-21 US disclosed
US-20220119391-A1 MACROCYCLIC COMPOUND AND USE THEREOF SCOHIA PHARMA, INC. (JP) 2022-04-21 US disclosed
CN-113164468-A Macrocyclic compounds and uses thereof 思可海雅药品公司 2021-07-23 CN disclosed
WO-2020116660-A1 MACROCYCLIC COMPOUND AND USE THEREOF SCOHIA PHARMA, INC. (JP) 2020-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11518763-B2 Macrocyclic compound and use thereof TFAM, KEAP1, FASTKD1 PSMD10 1062/4885CA12 4266/4885CA1 4500/4885
US-20220119391-A1 MACROCYCLIC COMPOUND AND USE THEREOF TFAM, KEAP1, CKMT1A; CKMT1B PSMD10 1122/4885CA12 4263/4885CA1 4436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.